- Home
- BGI vs ATHA Comparison
BGI vs ATHA Comparison
Compare BGI & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- ATHA
- Stock Information
- Founded
- BGI 1879
- ATHA 2011
- Country
- BGI Canada
- ATHA United States
- Employees
- BGI N/A
- ATHA N/A
- Industry
- BGI
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- BGI
- ATHA Health Care
- Exchange
- BGI Nasdaq
- ATHA Nasdaq
- Market Cap
- BGI 21.8M
- ATHA 21.0M
- IPO Year
- BGI 2005
- ATHA 2020
- Fundamental
- Price
- BGI $1.29
- ATHA $0.28
- Analyst Decision
- BGI
- ATHA Buy
- Analyst Count
- BGI 0
- ATHA 4
- Target Price
- BGI N/A
- ATHA $11.25
- AVG Volume (30 Days)
- BGI 71.4K
- ATHA 209.7K
- Earning Date
- BGI 11-27-2024
- ATHA 05-14-2025
- Dividend Yield
- BGI N/A
- ATHA N/A
- EPS Growth
- BGI N/A
- ATHA N/A
- EPS
- BGI N/A
- ATHA N/A
- Revenue
- BGI $131,596,265.00
- ATHA N/A
- Revenue This Year
- BGI N/A
- ATHA N/A
- Revenue Next Year
- BGI N/A
- ATHA N/A
- P/E Ratio
- BGI N/A
- ATHA N/A
- Revenue Growth
- BGI 4.01
- ATHA N/A
- 52 Week Low
- BGI $0.93
- ATHA $0.25
- 52 Week High
- BGI $3.42
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- BGI 57.94
- ATHA 31.57
- Support Level
- BGI $1.03
- ATHA $0.25
- Resistance Level
- BGI $1.24
- ATHA $0.33
- Average True Range (ATR)
- BGI 0.09
- ATHA 0.03
- MACD
- BGI 0.02
- ATHA -0.00
- Stochastic Oscillator
- BGI 78.79
- ATHA 26.67
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.